JP2018523092A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523092A5
JP2018523092A5 JP2017557192A JP2017557192A JP2018523092A5 JP 2018523092 A5 JP2018523092 A5 JP 2018523092A5 JP 2017557192 A JP2017557192 A JP 2017557192A JP 2017557192 A JP2017557192 A JP 2017557192A JP 2018523092 A5 JP2018523092 A5 JP 2018523092A5
Authority
JP
Japan
Prior art keywords
kda
measuring
sample
tbi
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017557192A
Other languages
English (en)
Japanese (ja)
Other versions
JP6839854B2 (ja
JP2018523092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/031043 external-priority patent/WO2016179426A1/en
Publication of JP2018523092A publication Critical patent/JP2018523092A/ja
Publication of JP2018523092A5 publication Critical patent/JP2018523092A5/ja
Application granted granted Critical
Publication of JP6839854B2 publication Critical patent/JP6839854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017557192A 2015-05-05 2016-05-05 星状細胞トラウマトーム（ｔｒａｕｍａｔｏｍｅ）および神経外傷のバイオマーカー Active JP6839854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157389P 2015-05-05 2015-05-05
US62/157,389 2015-05-05
PCT/US2016/031043 WO2016179426A1 (en) 2015-05-05 2016-05-05 Astrocyte traumatome and neurotrauma biomarkers

Publications (3)

Publication Number Publication Date
JP2018523092A JP2018523092A (ja) 2018-08-16
JP2018523092A5 true JP2018523092A5 (enExample) 2019-06-06
JP6839854B2 JP6839854B2 (ja) 2021-03-17

Family

ID=57218432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017557192A Active JP6839854B2 (ja) 2015-05-05 2016-05-05 星状細胞トラウマトーム（ｔｒａｕｍａｔｏｍｅ）および神経外傷のバイオマーカー

Country Status (7)

Country Link
US (3) US10557859B2 (enExample)
EP (1) EP3292414B1 (enExample)
JP (1) JP6839854B2 (enExample)
CN (1) CN107864671A (enExample)
ES (1) ES2873509T3 (enExample)
IL (1) IL255351A0 (enExample)
WO (1) WO2016179426A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292414B1 (en) * 2015-05-05 2021-04-07 The Regents of the University of California Astrocyte traumatome and neurotrauma biomarkers
US11709168B2 (en) * 2017-05-23 2023-07-25 Brainbox Solutions, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US11988676B2 (en) * 2017-11-16 2024-05-21 Brainbox Solutions, Inc. Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
EP3732489B1 (en) 2017-12-29 2025-10-22 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
GB0414798D0 (en) * 2004-07-01 2004-08-04 Paradigm Therapeutics Ltd Receptor
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
JP2011511301A (ja) * 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド 脳損傷を診断または治療するための方法
CA2766057A1 (en) 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
KR101211280B1 (ko) * 2010-03-26 2012-12-11 가톨릭대학교 산학협력단 신규한 뇌손상 질환 진단용 마커 및 이의 용도
MX2012013735A (es) * 2010-05-28 2013-04-29 Mind Nrg Sa Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
CN106461645A (zh) 2014-04-07 2017-02-22 铁马诊断公司 外伤性脑损伤和神经退行性生物标记物、方法和系统
AU2015322029A1 (en) 2014-09-25 2017-04-27 Oxeia Biopharmaceuticals, Inc. Methods of treating traumatic brain injury
EP3292414B1 (en) * 2015-05-05 2021-04-07 The Regents of the University of California Astrocyte traumatome and neurotrauma biomarkers

Similar Documents

Publication Publication Date Title
US11360103B2 (en) Alpha-synuclein detection assay and method for diagnosing alpha- synucleinopathies
DK2341350T3 (en) DIAGNOSTIC PROCEDURE FOR BRAKE INJURY-RELATED DISORDERS BASED ON DJ-1 DETECTION
JP2016533499A5 (enExample)
US11371991B2 (en) Diagnosis of a neuroautoimmune disease
JP2016105097A5 (enExample)
JP2018523092A5 (enExample)
ES2788389T3 (es) Ensayo mejorado para el diagnóstico de alergia al cacahuete
JP2013531784A5 (enExample)
AU2025202839A1 (en) Method for detecting inflammasome proteins as biomarkers of neurological disorders
CN110133272A (zh) 用于从生物体液中富集或检测星形胶质细胞来源的外泌体的方法
JP2018205327A (ja) 子癇前症を診断するための方法および組成物
Mukaetova-Ladinska et al. Alpha-and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes
WO2007090630A3 (en) Peptide aptamer for neutralizing the binding of platelet antigene specific antibodies and diagnostic and therapeutic applications containing the same
JP2016526167A5 (enExample)
Tanaka et al. Identification of tuberculosis-associated proteins in whole blood supernatant
EA025107B1 (ru) Способ диагностирования болезни альцгеймера, нейродегенерации при синдроме дауна или легкого когнитивного нарушения у субъекта (варианты) и набор для осуществления способа
CA2698437A1 (en) Marker sequences for rheumatoid arthritis and use thereof
WO2014080063A1 (es) Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
CN108431032B (zh) 纤维蛋白原捕捉剂检测ciz1 b变体的用途
DK1664795T3 (en) DIAGNOSTIC PROCEDURE FOR Brain Injury-Related Disorders
JP7693173B2 (ja) マカダミアナッツアレルゲン特異的ＩｇＥを検出するための方法、マカダミアナッツアレルギー診断用体外診断薬、マカダミアナッツアレルゲン特異的ＩｇＥ検出用キット、およびマカダミアナッツアレルゲンの検出方法
ES2992145T3 (es) Método para predecir o pronosticar la respuesta al tratamiento de la esclerosis múltiple con interferón beta
RU2627653C1 (ru) Способ контроля эффективности сорбции липополисахарида при проведении селективной липополисахаридной гемосорбции
Sveiven Development of magnetic assays for quantification of serum proteins and enzymatic activity
TO PERSISTENCE OF INFECTIOUS SARS-COV-2 PARTICLESFORUPTO37 DAYSIN PATIENTS WITH MILD COVID-19–P. 2053